查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2112452

心房顫動治療設備：市場洞察、競爭格局和市場預測 - 2034 年

Atrial Fibrillation Devices - Market Insights, Competitive Landscape, and Market Forecast - 2034
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

概述：

  • 2025年全球心房顫動治療設備市場價值為145億美元，預計2034年將達380億美元。
  • 預計從 2026 年到 2034 年，該市場將以 11.3% 的複合年成長率成長。這主要受以下因素驅動：由於人口老化導致心房顫動盛行率上升、脈衝電場消融的快速普及、為預防中風而進行的左心耳封堵術的增加，以及診斷和連續監測的擴展。
  • 以產品細分市場來看，預計到 2025 年，消融設備細分市場將佔 48% 的佔有率，成為治療心房顫動設備市場的領頭羊。
  • 就消融技術而言，預計到 2025 年，脈衝電場消融技術將佔 46% 的市場佔有率，從而推動心房顫動治療設備市場的發展。
  • 從適應症來看，陣發性心房顫動領域預計將在 2025 年引領市場，佔心房顫動治療設備市場的 54%。
  • 按最終用戶分類，預計到 2025 年，醫院領域將引領市場，在心房顫動治療設備市場中佔 66% 的市場佔有率。
  • 到 2025 年，北美將佔心房顫動治療設備市場 42% 的最大佔有率，但預計到 2034 年，亞太地區將實現最快的成長。

心房顫動治療設備是用於檢測、監測和治療心房顫動（最常見的持續性心律不整）的診斷和治療設備。本研究涵蓋消融設備，包括使用射頻、冷凍消融或脈衝電場能量隔離肺靜脈並治療心律不整的導管、產生器和主機；用於誘導消融的標測和記錄系統；用於預防中風的左心耳封堵器；以及診斷和監測設備，包括植入式循環記錄器和外部監視器。代表性產品包括波士頓科學公司的「FARAPULSE」和「WATCHMAN」、美Medtronic的「PulseSelect」和冷凍球囊、強生醫療科技公司的Biosense-Webster「VARIPULSE」和「CARTO」、雅培公司的「Amulet」和「EnSite」，以及來自Medtronic和其他公司的監測設備。該市場正經歷著向脈衝電場消融的快速轉變，這種技術能夠選擇性地消融心肌組織，同時保留周圍組織。目前市場的特點是脈衝電場消融的普及、左心耳封堵術的擴展以及監測技術的廣泛應用。

心房顫動治療設備市場的主要市場促進因素

  • 隨著人口老化，心房顫動的盛行率不斷上升，影響了相當一部分老年人，導致其發病率不斷上升。
  • 脈衝電場消融迅速普及，該技術可選擇性地消融心臟組織，同時保留食道和膈神經。
  • 左心耳封堵手術作為預防中風的口服抗凝血治療的替代方案，正變得越來越受歡迎。
  • 擴展診斷和連續監測功能，包括嵌入式循環記錄器和穿戴式/外部監測器。
  • 心導管電氣燒灼術術作為第一線有效心臟控制療法，實施數量增加。
  • 映射、影像和整合技術的進步提高了消融術的安全性和有效性。
  • 消融術和左心耳封堵術有強力的臨床證據和指引支持。

推動心房顫動治療設備市場成長的因素

市場促進因素

隨著年齡成長，心房顫動的盛行率也在增加。

推動心房顫動治療設備市場發展的根本動力是人口老化導致的心房顫動盛行率上升。心房顫動是最常見的持續性心律不整，影響相當一部分族群，且盛行率隨年齡增加而急劇上升。雖然心房顫動在一般人群中仍佔較小比例，但在65歲及以上人群中患病率較高，80歲及以上人群中患病率也相當高，近幾十年來，房顫的發病率和患病率一直在上升。隨著人口老化，心房顫動患者人數不斷增加，而高血壓、肥胖、糖尿病和心臟衰竭等心房顫動危險因子的盛行率上升進一步加劇了心房顫動的發生。心房顫動會增加中風、心臟衰竭和死亡的風險。此外，心房顫動患者數量龐大且持續成長，因此需要進行診斷、監測和治療，這推動了對心房顫動治療設備的需求。人口老化和風險因素的增加導致心房顫動盛行率上升，進而擴大了需要使用心房顫動治療設備進行診斷和治療的患者群體。隨著人口老化和心房顫動盛行率的上升，需要心房顫動治療設備的患者數量也在增加。人口老化導致的心房顫動盛行率上升，將為預測期內心房顫動治療設備市場的成長奠定基礎。

脈衝電場消融的迅速普及

脈衝電場消融的快速普及是推動消融市場變革、加速心房顫動治療設備發展的關鍵因素。脈衝電場消融利用組織選擇性電能消融引起心房顫動的心肌組織，同時保護食道和膈神經等周圍結構（這些結構可能因熱消融而受損），從而為肺靜脈隔離提供了一種更安全、更快捷的方法。自問世以來，脈衝電場消融發展迅速，首個獲準用於治療心房顫動的脈衝電場消融系統問世，目前市面上已有多種系統可供選擇。未來，預計這項技術將佔消融手術的大多數，取代射頻消融術和冷凍消融。包括波士頓科學公司的「FARAPULSE」、美敦Medtronic的「PulseSelect」、強生醫療科技公司的「VARIPULSE」以及雅培公司的系統在內的領先醫療設備製造商，已開發並推出了脈衝電場消融系統。這些系統的快速普及正在推動消融市場的成長和結構性變化。脈衝電場消融的安全性、快速性、有效性以及電生理學家對其的快速接受，正在推動消融領域和整個市場的成長。隨著脈衝電場消融的快速普及並取代熱消融，消融市場將擴大並向脈衝電場消融轉型。脈衝電場消融的快速普及將在整個預測期內維持並加速心房顫動治療設備市場的成長。

市場限制因素

心房顫動治療器械市場面臨許多相互關聯的限制因素，阻礙了其發展。其中最主要的因素是器械和手術成本。消融術和左心耳封堵術所需的器械和手術設備昂貴，包括導管、主機、標測系統、植入、專用設施和專業人員，這些成本會限制患者獲得治療的機會，尤其是在預算或資源有限的醫療系統中。對專業電生理設施、設備和訓練有素的電生理醫師的需求限制了消融術和封堵術的開展能力，而訓練有素的電生理醫師短缺和電生理檢查室容量不足又限制了手術數量。消融術和封堵術的複雜性、脈衝電場消融等新技術的學習曲線以及手術併發症的風險，都需要訓練和經驗，這些都可能成為限制其普及的因素。消融術後心房顫動復發（尤其是在持續性心房顫動病例中）以及再次治療的需求可能會影響部分患者的治療效果和提案。雖然保險報銷通常較為支持，但具體報銷金額會因醫療系統和手術類型而異，這可能會限制患者的就醫和治療普及。器械治療與藥物治療之間的競爭，以及適合器械治療的患者選擇，決定了目標患者群體。技術的快速發展，特別是脈衝電場消融的興起，需要持續的投資，並可能促使舊技術的淘汰。電生理檢查和器械治療的普及程度存在區域差異，尤其是在新興市場，這限制了市場擴張。這些因素共同導致了器械治療普及速度和範圍的緩慢，因此，製造商需要證明器械治療的安全性、有效性、成本效益和價值，並支持培訓和基礎設施建設，才能維持市場成長。

目錄

第1章：心房顫動治療器材市場：引言

  • 調查範圍
  • 市場區隔
  • 市場概覽

第2章：心房顫動治療器材市場：摘要整理

  • 主要亮點和市場概覽

第3章：心房顫動治療設備市場：關鍵因素分析

  • 市場促進因素
    • 隨著人口老化，心房顫動的盛行率正在增加。
    • 脈衝電場消融的迅速普及
    • 左心耳封堵術在預防中風方面已廣泛應用。
    • 監測、手術次數、映射和臨床證據
  • 市場限制因素
    • 設備和治療費用
    • 設備容量、訓練和流程複雜程度
    • 復發、保險報銷和使用限制
  • 市場機遇
    • 脈衝電場消融、封堵術及持續性心房顫動
    • 新興市場及監測

第4章：人工智慧、地緣政治、貿易與經濟趨勢

第5章：監理分析

  • 美國
  • 歐洲
  • 日本
  • 中國

第6章：波特五力分析

第7章：心房顫動治療設備市場：評估

  • 依產品
    • 消融裝置
    • 測繪和記錄設備
    • 左心房耳廓閉合裝置
    • 診斷和監測設備
  • 消融技術
    • 脈衝電場消融
    • 射頻消融術
    • 冷凍消融術
    • 其他
  • 適應症
    • 陣發性心房顫
    • 持續性心房顫動
    • 持續性心房顫
  • 最終用戶
    • 醫院
    • 門診手術中心
    • 專科心臟診所
  • 按地區
    • 北美洲
    • 歐洲
    • 亞太地區
    • 世界其他地區

第8章：心房顫動治療器材市場：競爭格局

  • 競爭分析
  • 企業市場占有率分析（加值服務）

第9章：心房顫動治療設備市場：新創企業資金籌措與投資趨勢

第10章：心房顫動治療設備市場：公司概況與產品概況

  • Boston Scientific Corporation
  • Medtronic plc
  • Johnson & Johnson MedTech
  • Abbott Laboratories
  • AtriCure, Inc.
  • Biotronik SE & Co. KG
  • MicroPort Scientific Corporation
  • Koninklijke Philips NV
  • GE HealthCare Technologies Inc.
  • Stereotaxis, Inc.

第11章：KOL的觀點

第12章：專案式教學方法

第13章：關於 DelveInsight

第14章 免責聲明與聯絡方式

Product Code: DIMDCL0968

Atrial Fibrillation Devices Market Summary

Overview:

  • The global atrial fibrillation devices market was valued at USD 14.50 billion in 2025 and is projected to reach USD 38.00 billion by 2034.
  • The market is expected to expand at a CAGR of 11.3% during the forecast period 2026-2034, supported by the rising prevalence of atrial fibrillation with the aging population, the rapid adoption of pulsed field ablation, the growth of left atrial appendage closure for stroke prevention, and the expansion of diagnosis and continuous monitoring.
  • By product, the ablation devices segment dominated the atrial fibrillation devices market with a 48% share in 2025.
  • By ablation technology, the pulsed field ablation segment dominated the atrial fibrillation devices market with a 46% share in 2025.
  • By indication, the paroxysmal atrial fibrillation segment dominated the atrial fibrillation devices market with a 54% share in 2025.
  • By end-user, the hospitals segment dominated the atrial fibrillation devices market with a 66% share in 2025.
  • North America accounted for the largest share of the atrial fibrillation devices market at 42% in 2025, while Asia-Pacific is anticipated to register the fastest growth through 2034.

Atrial fibrillation devices are the diagnostic and therapeutic devices used to detect, monitor, and treat atrial fibrillation, the most common sustained cardiac arrhythmia. The scope encompasses ablation devices, including the catheters, generators, and consoles that use radiofrequency, cryoablation, and pulsed field energy to isolate the pulmonary veins and eliminate the arrhythmia, mapping and recording systems that guide ablation, left atrial appendage closure devices that prevent stroke, and diagnostic and monitoring devices, including implantable loop recorders and external monitors. Leading products include the Boston Scientific FARAPULSE and WATCHMAN, the Medtronic PulseSelect and cryoballoon, the Johnson and Johnson MedTech Biosense Webster VARIPULSE and CARTO, the Abbott portfolio including the Amulet and EnSite, and the monitoring devices of Medtronic and others. The market is undergoing a rapid transition to pulsed field ablation, which selectively ablates cardiac tissue while sparing surrounding structures, and the contemporary market is defined by the adoption of pulsed field ablation, the growth of left atrial appendage closure, and the expansion of monitoring.

Atrial Fibrillation Devices Market Key Growth Drivers

  • Rising prevalence of atrial fibrillation with the aging population, affecting a substantial share of the elderly and rising in incidence.
  • Rapid adoption of pulsed field ablation, which selectively ablates cardiac tissue while sparing the esophagus and phrenic nerve.
  • Growth of left atrial appendage closure for stroke prevention as an alternative to oral anticoagulation.
  • Expansion of diagnosis and continuous monitoring, including implantable loop recorders and wearable and external monitors.
  • Increasing procedural volume of catheter ablation as a first-line and effective rhythm control therapy.
  • Advances in mapping, imaging, and integration that improve the safety and efficacy of ablation.
  • Strong clinical evidence and guideline support for ablation and left atrial appendage closure.

Key Companies in Atrial Fibrillation Devices Market

The competitive field is led by cardiac rhythm and electrophysiology device companies, challenged by monitoring and specialty ablation companies. The leading participants in the atrial fibrillation devices market include the following:

  • Boston Scientific Corporation
  • Medtronic plc
  • Johnson & Johnson MedTech
  • Abbott Laboratories
  • AtriCure, Inc.
  • Biotronik SE & Co. KG
  • MicroPort Scientific Corporation
  • Koninklijke Philips N.V.
  • GE HealthCare Technologies Inc.
  • Stereotaxis, Inc.

Factors Contributing to the Growth of the Atrial Fibrillation Devices Market

Market Drivers

Rising Prevalence of Atrial Fibrillation with the Aging Population

The foundational driver of the atrial fibrillation devices market is the rising prevalence of atrial fibrillation, driven by the aging of the population. Atrial fibrillation is the most common sustained cardiac arrhythmia, affecting a substantial share of the population that rises steeply with age; a small percentage of the general population, a larger share of those over sixty-five, and a substantial share of those over eighty, and the incidence and prevalence of atrial fibrillation have risen over recent decades. The aging of the population increases the number of people with atrial fibrillation, and the rising prevalence of the risk factors of atrial fibrillation, including hypertension, obesity, diabetes, and heart failure, further increases its incidence. Atrial fibrillation increases the risk of stroke, heart failure, and mortality, and the large and growing population of patients with atrial fibrillation requires diagnosis, monitoring, and treatment, driving the demand for atrial fibrillation devices. The rising prevalence of atrial fibrillation, driven by aging and the growth of risk factors, enlarges the population requiring the diagnosis and treatment that atrial fibrillation devices provide. As the population ages and as the prevalence of atrial fibrillation rises, the number of patients requiring atrial fibrillation devices grows in step. The rising prevalence of atrial fibrillation with the aging population anchors the growth of the atrial fibrillation devices market across the forecast period.

Rapid Adoption of Pulsed Field Ablation

The rapid adoption of pulsed field ablation is a defining driver that is transforming the ablation market and accelerating the growth of atrial fibrillation devices. Pulsed field ablation uses tissue-selective electrical energy to ablate the cardiac tissue that causes atrial fibrillation while sparing the surrounding structures, including the esophagus and phrenic nerve, that thermal ablation can damage, and it offers a safer and faster approach to pulmonary vein isolation. Pulsed field ablation has been adopted rapidly since its introduction, with the first pulsed field ablation system approved for atrial fibrillation and multiple systems now available, and it is expected to account for the majority of ablation procedures, displacing radiofrequency and cryoablation. The leading device companies have developed and launched pulsed field ablation systems, including the Boston Scientific FARAPULSE, the Medtronic PulseSelect, the Johnson and Johnson MedTech VARIPULSE, and the Abbott system, and the rapid adoption of these systems drives the growth and the shift of the ablation market. The safety, speed, and efficacy of pulsed field ablation, and its rapid adoption by electrophysiologists, drive the growth of the ablation segment and the market. As pulsed field ablation is adopted rapidly and as it displaces thermal ablation, the ablation market grows and shifts toward pulsed field ablation. The rapid adoption of pulsed field ablation sustains and accelerates the growth of the atrial fibrillation devices market across the forecast period.

Market Restraints

The atrial fibrillation devices market faces several interrelated restraints that temper its growth. The foremost is the cost of devices and procedures, since ablation and left atrial appendage closure devices and procedures are costly, requiring expensive catheters, consoles, mapping systems, implants, specialized facilities and staff, and the cost can constrain access, particularly in cost-constrained systems and lower-resource settings. The requirement for specialized electrophysiology facilities, equipment, and trained electrophysiologists constrains the capacity to perform ablation and closure, and the shortage of trained electrophysiologists and the capacity of electrophysiology laboratories limit procedural volume. The complexity of ablation and closure procedures, the learning curve of new technologies such as pulsed field ablation, and the risk of procedural complications require training and experience and can limit adoption. The recurrence of atrial fibrillation after ablation, particularly in persistent atrial fibrillation, and the need for repeat procedures temper the outcomes and the value proposition for some patients. Reimbursement, while generally supportive, varies across systems and procedures and can constrain access and adoption. The competition of devices with drug therapy and the appropriate selection of patients for device therapy shape the addressable population. The rapid pace of technological change, particularly the transition to pulsed field ablation, requires continuous investment and can strand prior technology. The variability of access to electrophysiology and device therapy across regions, particularly in emerging markets, constrains the market. Together, these factors moderate the pace and scope of adoption and require manufacturers to demonstrate safety, efficacy, cost-effectiveness, and value and to support training and capacity to sustain growth.

Atrial Fibrillation Devices Market Segment Analysis

The global atrial fibrillation devices market is segmented by product (ablation devices, mapping and recording devices, left atrial appendage closure devices, diagnostic and monitoring devices), by ablation technology (pulsed field ablation, radiofrequency ablation, cryoablation, others), by indication (paroxysmal atrial fibrillation, persistent atrial fibrillation, long-standing persistent atrial fibrillation), by end-users (hospitals, ambulatory surgical centers, specialized cardiac clinics, and others), and by geography (North America, Europe, Asia-Pacific, and the Rest of the World).

By Product

Dominant Subsegment: Ablation Devices.

The ablation devices category is expected to dominate the market. The ablation devices segment accounted for a 48% share of the atrial fibrillation devices market in 2025. Ablation devices, including the catheters, generators, and consoles that ablate the cardiac tissue causing atrial fibrillation, are the leading product category because catheter ablation is the principal interventional therapy for atrial fibrillation and the ablation procedure consumes high-value catheters and consumables in growing volume. The dominance of the segment reflects the central role of catheter ablation in the treatment of atrial fibrillation, the high value of ablation catheters and systems, and the rapid growth and transition of ablation driven by pulsed field ablation. Ablation devices isolate the pulmonary veins to eliminate the source of atrial fibrillation using radiofrequency, cryoablation, and pulsed field energy, and the leading companies provide ablation catheters, generators, and consoles, including the rapidly adopted pulsed field ablation systems. The central role of ablation, the value of the devices, the growth of procedural volume, and the transition to pulsed field ablation drive the ablation devices segment. While mapping and recording systems, left atrial appendage closure devices, and diagnostic and monitoring devices are important product categories, the centrality, value, and growth of ablation devices sustain the leadership of the ablation devices segment across the forecast period.

By Ablation Technology

Dominant Subsegment: Pulsed Field Ablation.

The pulsed field ablation category is expected to dominate the market. The pulsed field ablation segment accounted for a 46% share of the atrial fibrillation devices ablation market in 2025. Pulsed field ablation, which uses tissue-selective electrical energy to ablate cardiac tissue while sparing surrounding structures, is the leading ablation technology because it has been adopted rapidly since its introduction and is displacing radiofrequency and cryoablation to become the predominant ablation modality. The dominance of the segment reflects the rapid adoption of pulsed field ablation, its safety and speed advantages over thermal ablation, and its embrace by electrophysiologists and the leading device companies. Pulsed field ablation spares the esophagus and phrenic nerve that thermal ablation can damage, isolates the pulmonary veins safely and quickly, and has been adopted rapidly, with the leading companies launching pulsed field ablation systems and the technology expected to account for the majority of ablation procedures. The safety, speed, efficacy, and rapid adoption of pulsed field ablation, and the investment of the leading companies, drive the segment. While radiofrequency ablation, the established modality, and cryoablation remain significant and widely used, the rapid adoption, advantages, and momentum of pulsed field ablation sustain the leadership of the pulsed field ablation segment across the forecast period, and it defines the direction of the ablation market.

Atrial Fibrillation Devices Market Region Analysis

Dominant Region: North America

North America accounted for a 42% share of the global atrial fibrillation devices market in 2025, representing the highest regional market share globally. The leadership of the region reflects the high prevalence and diagnosis of atrial fibrillation, the advanced adoption of ablation and left atrial appendage closure, the presence and headquarters of the leading device companies, and supportive reimbursement. The United States is the largest national market, supported by the high prevalence and diagnosis of atrial fibrillation, the advanced electrophysiology infrastructure, the rapid adoption of pulsed field ablation and left atrial appendage closure, the presence of the leading device companies, and the supportive reimbursement of ablation and closure. The advanced electrophysiology infrastructure, the high procedural volume, the rapid adoption of new technologies, and the strong reimbursement drive the market, and the leading device companies are headquartered and conduct extensive development and commercialization in the region. The high prevalence and diagnosis, the advanced adoption, the presence of the leading companies, and the supportive reimbursement reinforce the leadership of the region. The combination of disease burden, adoption maturity, company presence, and reimbursement sustains the position of North America as the largest regional market across the forecast period.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is projected to register the fastest compound annual growth rate through 2034. The region combines large and aging populations, the rising prevalence and diagnosis of atrial fibrillation, the expansion of electrophysiology infrastructure, and the growing adoption of ablation and closure, which drives the fast growth of the market. China, Japan, and India are the principal national markets, supported by the aging of large populations, the rising prevalence and diagnosis of atrial fibrillation, the expansion of electrophysiology laboratories and cardiac centers, the adoption of ablation and left atrial appendage closure, and the growth of healthcare investment and access. The growth of the atrial fibrillation population, the expansion of electrophysiology infrastructure, and the adoption of advanced devices enlarge the demand for atrial fibrillation devices. As populations age, as the diagnosis of atrial fibrillation increases, and as electrophysiology infrastructure and the adoption of ablation and closure expand, the region increases its demand from a growing base, and the scale of the population and the expansion of infrastructure create substantial long-term demand. The combination of population scale, rising disease burden, infrastructure expansion, and device adoption positions Asia-Pacific as the fastest-growing regional market, and it attracts investment and commercial focus from the leading global device companies.

Regional Commentary

North America

North America leads the market, supported by the high prevalence and diagnosis of atrial fibrillation, the advanced adoption of ablation and left atrial appendage closure, the presence of the leading device companies, and supportive reimbursement. The United States dominates the region through its advanced electrophysiology infrastructure, the rapid adoption of pulsed field ablation and closure, and the presence of the leading companies. The high procedural volume and reimbursement sustain demand.

Europe

Europe is a substantial market shaped by advanced healthcare systems, the adoption of ablation and left atrial appendage closure, and the presence and development of the leading device companies. Germany, the United Kingdom, France, Italy, and Spain are the principal national markets, supported by the prevalence of atrial fibrillation, the adoption of pulsed field ablation and closure, and the electrophysiology infrastructure. Demand is sustained by the disease burden, the adoption of advanced devices, and the support of clinical evidence and guidelines.

Asia-Pacific

Asia-Pacific is the fastest-growing region, driven by large and aging populations, the rising prevalence and diagnosis of atrial fibrillation, the expansion of electrophysiology infrastructure, and the growing adoption of ablation and closure across China, Japan, and India. Aging populations, rising disease burden, and infrastructure expansion sustain rapid growth, and the region attracts commercial focus from the leading global device companies.

Rest of World

The Rest of World, spanning Latin America, the Middle East, and Africa, represents an emerging opportunity as the diagnosis of atrial fibrillation and electrophysiology infrastructure grow. Growth is supported by the rising prevalence and diagnosis of atrial fibrillation, the expansion of cardiac and electrophysiology infrastructure, and the growing adoption of ablation and closure, though access and infrastructure vary by market. Device companies pursue these markets through devices and training suited to expanding electrophysiology.

Atrial Fibrillation Devices Market Competitive Landscape

The global atrial fibrillation devices market is classified as Consolidated. A small group of large cardiac rhythm and electrophysiology device companies holds the majority of the market through comprehensive portfolios spanning ablation, mapping, closure, and monitoring, while specialty ablation, monitoring, and robotics companies compete in specific segments. Competition centers on the performance and safety of ablation, particularly the transition to pulsed field ablation, the integration of ablation with mapping, the breadth of the portfolio across ablation, closure, and monitoring, clinical evidence, and the training and support of electrophysiologists. The pulsed field ablation transition, product launches, and clinical trials intensify the contest. The competitive landscape is evaluated across the following dimensions:

  • Market concentration: Consolidated, with a small group of large cardiac rhythm and electrophysiology device companies holding the majority of the market, alongside specialty ablation, monitoring, and robotics companies.
  • Leading players: Boston Scientific, Medtronic, Johnson & Johnson MedTech through Biosense Webster, and Abbott lead across ablation, mapping, closure, and monitoring, and AtriCure, Biotronik, MicroPort, Philips, GE HealthCare, and Stereotaxis contest ablation, imaging, monitoring, and robotics.
  • Geographic reach: The leading companies operate global commercial, clinical, and training organizations, with the strongest presence in North America and Europe and an expanding presence in Asia-Pacific.
  • Product portfolio strength: Competitive advantage rests on the breadth and performance of the portfolio across ablation, particularly pulsed field ablation, mapping and integration, left atrial appendage closure, and monitoring, and on the clinical evidence supporting the devices.
  • Pipeline strength: Development is concentrated in pulsed field ablation, the integration of pulsed field ablation with mapping, next-generation left atrial appendage closure, and monitoring and artificial intelligence.
  • Strategic partnerships: Collaboration spans the integration of ablation and mapping, partnerships and acquisitions that add pulsed field ablation and closure technology, and clinical trial collaborations.
  • M&A activity: Consolidation has shaped the field, with the leading companies acquiring pulsed field ablation, closure, and mapping technologies to build comprehensive portfolios, exemplified by acquisitions that added pulsed field ablation capability.
  • Innovation focus: Innovation is shifting toward pulsed field ablation and its integration with mapping, next-generation closure devices, combined ablation and closure, and monitoring and artificial intelligence.
  • Regulatory standing: Approval and clearance by the Food and Drug Administration and conformity under the European Union Medical Device Regulation, and the strong clinical evidence supporting ablation and closure, are decisive competitive credentials and a principal axis of competition among the leaders.

Atrial Fibrillation Devices Market Recent Developmental Activities

In late 2023, Medtronic plc received Food and Drug Administration approval for the PulseSelect pulsed field ablation system, the first pulsed field ablation system approved for atrial fibrillation in the United States. Strategic significance: the approval marked the arrival of pulsed field ablation in the United States and initiated the rapid transition of the ablation market.

In 2024, Boston Scientific Corporation advanced and commercialized the FARAPULSE pulsed field ablation system, which achieved rapid adoption and strong clinical outcomes in pulmonary vein isolation. Strategic significance: the commercialization of FARAPULSE established a leading position in pulsed field ablation and drove the transition of the ablation market.

Atrial Fibrillation Devices Market Segmentation

Atrial Fibrillation Devices Market Assessment by Product

  • Ablation Devices
  • Mapping and Recording Devices
  • Left Atrial Appendage Closure Devices
  • Diagnostic and Monitoring Devices

Atrial Fibrillation Devices Market Assessment by Ablation Technology

  • Pulsed Field Ablation
  • Radiofrequency Ablation
  • Cryoablation
  • Others

Atrial Fibrillation Devices Market Assessment by Indication

  • Paroxysmal Atrial Fibrillation
  • Persistent Atrial Fibrillation
  • Long-Standing Persistent Atrial Fibrillation

Atrial Fibrillation Devices Market Assessment by End-User

  • Hospitals
  • Ambulatory Surgical Centers
  • Specialized Cardiac Clinics
  • Others

Atrial Fibrillation Devices Market Assessment by Geography

  • North America
  • United States Atrial Fibrillation Devices Market Size in USD million (2023-2034)
  • Canada Atrial Fibrillation Devices Market Size in USD million (2023-2034)
  • Mexico Atrial Fibrillation Devices Market Size in USD million (2023-2034)
  • Europe
  • Germany Atrial Fibrillation Devices Market Size in USD million (2023-2034)
  • United Kingdom Atrial Fibrillation Devices Market Size in USD million (2023-2034)
  • France Atrial Fibrillation Devices Market Size in USD million (2023-2034)
  • Italy Atrial Fibrillation Devices Market Size in USD million (2023-2034)
  • Spain Atrial Fibrillation Devices Market Size in USD million (2023-2034)
  • Rest of Europe Atrial Fibrillation Devices Market Size in USD million (2023-2034)
  • Asia-Pacific
  • China Atrial Fibrillation Devices Market Size in USD million (2023-2034)
  • Japan Atrial Fibrillation Devices Market Size in USD million (2023-2034)
  • India Atrial Fibrillation Devices Market Size in USD million (2023-2034)
  • Australia Atrial Fibrillation Devices Market Size in USD million (2023-2034)
  • South Korea Atrial Fibrillation Devices Market Size in USD million (2023-2034)
  • Rest of Asia-Pacific Atrial Fibrillation Devices Market Size in USD million (2023-2034)
  • Rest of the World
  • Middle East Atrial Fibrillation Devices Market Size in USD million (2023-2034)
  • Africa Atrial Fibrillation Devices Market Size in USD million (2023-2034)
  • South America Atrial Fibrillation Devices Market Size in USD million (2023-2034)

Key Takeaways from the Atrial Fibrillation Devices Market Report Study

  • Market size analysis for the current atrial fibrillation devices market size (2025), and market forecast for 9 years (2026 to 2034).
  • Top key device and technology developments, approvals, clinical trials, and acquisitions that happened over the last 3 years.
  • Key companies dominating the global atrial fibrillation devices market.
  • Various opportunities available for competitors in the atrial fibrillation devices market space.
  • What are the top-performing segments in 2025? How will these segments perform in 2034?
  • Which are the top-performing regions and countries in the current atrial fibrillation devices market scenario?
  • Which are the regions and countries where companies should concentrate their opportunities for atrial fibrillation devices market growth in the future?

Target audience who can benefit from this atrial fibrillation devices market report study

  • Atrial fibrillation device, electrophysiology, and cardiac rhythm management providers
  • Research organizations and consulting companies
  • Cardiology and electrophysiology-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Hospitals, cardiac centers, and distributors dealing in atrial fibrillation devices
  • Various end-users who want to know more about the atrial fibrillation devices market and the latest technological developments in the atrial fibrillation devices market.

Frequently Asked Questions:

Q1. At what rate is the atrial fibrillation devices market expected to grow?

The global atrial fibrillation devices market is projected to grow at a compound annual growth rate of 11.3% during the forecast period from 2026 to 2034.

Q2. What is the current and projected size of the atrial fibrillation devices market?

The global atrial fibrillation devices market was valued at USD 14.50 billion in 2025 and is projected to reach USD 38.00 billion by 2034.

Q3. Which region dominates the atrial fibrillation devices market?

North America dominated the atrial fibrillation devices market with a 42% share in 2025, driven by the high prevalence and diagnosis of atrial fibrillation, the advanced adoption of ablation and left atrial appendage closure, the presence of the leading device companies, and supportive reimbursement. Asia-Pacific is projected to record the fastest compound annual growth rate through 2034, driven by large and aging populations and the expansion of electrophysiology infrastructure across China, Japan, and India.

Q4. What are the key factors driving growth in the atrial fibrillation devices market?

The principal drivers are the rising prevalence of atrial fibrillation with the aging population; the rapid adoption of pulsed field ablation, which spares surrounding structures; the growth of left atrial appendage closure for stroke prevention; the expansion of diagnosis and continuous monitoring; the increasing procedural volume of catheter ablation; and the strong clinical evidence and guideline support for ablation and closure.

Q5. Who are the major players in the atrial fibrillation devices market?

The market is consolidated and led by Boston Scientific Corporation, Medtronic plc, Johnson & Johnson MedTech, and Abbott Laboratories, alongside AtriCure, Inc., Biotronik SE & Co. KG, MicroPort Scientific Corporation, Koninklijke Philips N.V., GE HealthCare Technologies Inc., and Stereotaxis, Inc. Additional participants including CardioFocus, Inc., Adagio Medical, Inc., and Kardium Inc. compete across ablation, closure, mapping, and monitoring.

Table of Contents

1. Atrial Fibrillation Devices Market Introduction

  • 1.1. Scope of the Report
  • 1.2. Market Segmentation
  • 1.3. Market Overview at a Glance

2. Atrial Fibrillation Devices Market Executive Summary

  • 2.1. Key Highlights and Market Snapshot

3. Atrial Fibrillation Devices Market Key Factors Analysis

  • 3.1. Market Drivers
    • 3.1.1. Rising Prevalence of Atrial Fibrillation with the Aging Population
    • 3.1.2. Rapid Adoption of Pulsed Field Ablation
    • 3.1.3. Growth of Left Atrial Appendage Closure for Stroke Prevention
    • 3.1.4. Monitoring, Procedural Volume, Mapping, and Clinical Evidence
  • 3.2. Market Restraints
    • 3.2.1. Cost of Devices and Procedures
    • 3.2.2. Capacity, Training, and Procedural Complexity
    • 3.2.3. Recurrence, Reimbursement, and Access Constraints
  • 3.3. Market Opportunities
    • 3.3.1. Pulsed Field Ablation, Closure, and Persistent Atrial Fibrillation
    • 3.3.2. Emerging Markets and Monitoring

4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments

5. Regulatory Analysis

  • 5.1. The United States
  • 5.2. Europe
  • 5.3. Japan
  • 5.4. China

6. Atrial Fibrillation Devices Market Porter's Five Forces Analysis

  • 6.1. Bargaining Power of Suppliers
  • 6.2. Bargaining Power of Consumers
  • 6.3. Threat of New Entrants
  • 6.4. Threat of Substitutes
  • 6.5. Competitive Rivalry

7. Atrial Fibrillation Devices Market Assessment

  • 7.1. By Product
    • 7.1.1. Ablation Devices
    • 7.1.2. Mapping and Recording Devices
    • 7.1.3. Left Atrial Appendage Closure Devices
    • 7.1.4. Diagnostic and Monitoring Devices
  • 7.2. By Ablation Technology
    • 7.2.1. Pulsed Field Ablation
    • 7.2.2. Radiofrequency Ablation
    • 7.2.3. Cryoablation
    • 7.2.4. Others
  • 7.3. By Indication
    • 7.3.1. Paroxysmal Atrial Fibrillation
    • 7.3.2. Persistent Atrial Fibrillation
    • 7.3.3. Long-Standing Persistent Atrial Fibrillation
  • 7.4. By End-User
    • 7.4.1. Hospitals
    • 7.4.2. Ambulatory Surgical Centers
    • 7.4.3. Specialized Cardiac Clinics
    • 7.4.4. Others
  • 7.5. By Geography
    • 7.5.1. North America
      • 7.5.1.1. United States Atrial Fibrillation Devices Market Size in USD million (2023-2034)
      • 7.5.1.2. Canada Atrial Fibrillation Devices Market Size in USD million (2023-2034)
      • 7.5.1.3. Mexico Atrial Fibrillation Devices Market Size in USD million (2023-2034)
    • 7.5.2. Europe
      • 7.5.2.1. Germany Atrial Fibrillation Devices Market Size in USD million (2023-2034)
      • 7.5.2.2. United Kingdom Atrial Fibrillation Devices Market Size in USD million (2023-2034)
      • 7.5.2.3. France Atrial Fibrillation Devices Market Size in USD million (2023-2034)
      • 7.5.2.4. Italy Atrial Fibrillation Devices Market Size in USD million (2023-2034)
      • 7.5.2.5. Spain Atrial Fibrillation Devices Market Size in USD million (2023-2034)
      • 7.5.2.6. Rest of Europe Atrial Fibrillation Devices Market Size in USD million (2023-2034)
    • 7.5.3. Asia-Pacific
      • 7.5.3.1. China Atrial Fibrillation Devices Market Size in USD million (2023-2034)
      • 7.5.3.2. Japan Atrial Fibrillation Devices Market Size in USD million (2023-2034)
      • 7.5.3.3. India Atrial Fibrillation Devices Market Size in USD million (2023-2034)
      • 7.5.3.4. Australia Atrial Fibrillation Devices Market Size in USD million (2023-2034)
      • 7.5.3.5. South Korea Atrial Fibrillation Devices Market Size in USD million (2023-2034)
      • 7.5.3.6. Rest of Asia-Pacific Atrial Fibrillation Devices Market Size in USD million (2023-2034)
    • 7.5.4. Rest of the World
      • 7.5.4.1. Middle East Atrial Fibrillation Devices Market Size in USD million (2023-2034)
      • 7.5.4.2. Africa Atrial Fibrillation Devices Market Size in USD million (2023-2034)
      • 7.5.4.3. South America Atrial Fibrillation Devices Market Size in USD million (2023-2034)

8. Atrial Fibrillation Devices Market Competitive Landscape

  • 8.1. Competitive Analysis
  • 8.2. Company Share Analysis (Premium Offering)

9. Atrial Fibrillation Devices Market Startup Funding and Investment Trends

10. Atrial Fibrillation Devices Market Company and Product Profiles

  • 10.1. Boston Scientific Corporation
    • 10.1.1. Company Overview
    • 10.1.2. Company Snapshot
    • 10.1.3. Financial Overview
    • 10.1.4. Product Portfolio
    • 10.1.5. Strategic Initiatives / Entropy
  • 10.2. Medtronic plc
    • 10.2.1. Company Overview
    • 10.2.2. Company Snapshot
    • 10.2.3. Financial Overview
    • 10.2.4. Product Portfolio
    • 10.2.5. Strategic Initiatives / Entropy
  • 10.3. Johnson & Johnson MedTech
    • 10.3.1. Company Overview
    • 10.3.2. Company Snapshot
    • 10.3.3. Financial Overview
    • 10.3.4. Product Portfolio
    • 10.3.5. Strategic Initiatives / Entropy
  • 10.4. Abbott Laboratories
    • 10.4.1. Company Overview
    • 10.4.2. Company Snapshot
    • 10.4.3. Financial Overview
    • 10.4.4. Product Portfolio
    • 10.4.5. Strategic Initiatives / Entropy
  • 10.5. AtriCure, Inc.
    • 10.5.1. Company Overview
    • 10.5.2. Company Snapshot
    • 10.5.3. Financial Overview
    • 10.5.4. Product Portfolio
    • 10.5.5. Strategic Initiatives / Entropy
  • 10.6. Biotronik SE & Co. KG
    • 10.6.1. Company Overview
    • 10.6.2. Company Snapshot
    • 10.6.3. Financial Overview
    • 10.6.4. Product Portfolio
    • 10.6.5. Strategic Initiatives / Entropy
  • 10.7. MicroPort Scientific Corporation
    • 10.7.1. Company Overview
    • 10.7.2. Company Snapshot
    • 10.7.3. Financial Overview
    • 10.7.4. Product Portfolio
    • 10.7.5. Strategic Initiatives / Entropy
  • 10.8. Koninklijke Philips N.V.
    • 10.8.1. Company Overview
    • 10.8.2. Company Snapshot
    • 10.8.3. Financial Overview
    • 10.8.4. Product Portfolio
    • 10.8.5. Strategic Initiatives / Entropy
  • 10.9. GE HealthCare Technologies Inc.
    • 10.9.1. Company Overview
    • 10.9.2. Company Snapshot
    • 10.9.3. Financial Overview
    • 10.9.4. Product Portfolio
    • 10.9.5. Strategic Initiatives / Entropy
  • 10.10. Stereotaxis, Inc.
    • 10.10.1. Company Overview
    • 10.10.2. Company Snapshot
    • 10.10.3. Financial Overview
    • 10.10.4. Product Portfolio
    • 10.10.5. Strategic Initiatives / Entropy

For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.

11. KOL Views

12. Project Approach

13. About DelveInsight

14. Disclaimer and Contact Us

List of Tables

  • Table 1: Global Atrial Fibrillation Devices Market Size in USD million (2023-2034)
  • Table 2: Global Atrial Fibrillation Devices Market Size by Product in USD million (2023-2034)
  • Table 3: Global Atrial Fibrillation Devices Market Size by Ablation Technology in USD million (2023-2034)
  • Table 4: Global Atrial Fibrillation Devices Market Size by Indication in USD million (2023-2034)
  • Table 5: Global Atrial Fibrillation Devices Market Size by End-User in USD million (2023-2034)
  • Table 6: Atrial Fibrillation Devices Market Size in North America in USD million (2023-2034)
  • Table 7: Atrial Fibrillation Devices Market Size in the United States in USD million (2023-2034)
  • Table 8: Atrial Fibrillation Devices Market Size in Canada in USD million (2023-2034)
  • Table 9: Atrial Fibrillation Devices Market Size in Mexico in USD million (2023-2034)
  • Table 10: Atrial Fibrillation Devices Market Size in Europe in USD million (2023-2034)
  • Table 11: Atrial Fibrillation Devices Market Size in Germany in USD million (2023-2034)
  • Table 12: Atrial Fibrillation Devices Market Size in the United Kingdom in USD million (2023-2034)
  • Table 13: Atrial Fibrillation Devices Market Size in France in USD million (2023-2034)
  • Table 14: Atrial Fibrillation Devices Market Size in Italy in USD million (2023-2034)
  • Table 15: Atrial Fibrillation Devices Market Size in Spain in USD million (2023-2034)
  • Table 16: Atrial Fibrillation Devices Market Size in the Rest of Europe in USD million (2023-2034)
  • Table 17: Atrial Fibrillation Devices Market Size in Asia-Pacific in USD million (2023-2034)
  • Table 18: Atrial Fibrillation Devices Market Size in China in USD million (2023-2034)
  • Table 19: Atrial Fibrillation Devices Market Size in Japan in USD million (2023-2034)
  • Table 20: Atrial Fibrillation Devices Market Size in India in USD million (2023-2034)
  • Table 21: Atrial Fibrillation Devices Market Size in Australia in USD million (2023-2034)
  • Table 22: Atrial Fibrillation Devices Market Size in South Korea in USD million (2023-2034)
  • Table 23: Atrial Fibrillation Devices Market Size in the Rest of Asia-Pacific in USD million (2023-2034)
  • Table 24: Atrial Fibrillation Devices Market Size in the Rest of the World in USD million (2023-2034)
  • Table 25: Atrial Fibrillation Devices Market Size in the Middle East in USD million (2023-2034)
  • Table 26: Atrial Fibrillation Devices Market Size in Africa in USD million (2023-2034)
  • Table 27: Atrial Fibrillation Devices Market Size in South America in USD million (2023-2034)
  • Table 28: Atrial Fibrillation Devices Market Competitive Landscape
  • Table 29: Atrial Fibrillation Devices Market Startup Funding and Investment Trends

List of Figures

  • Figure 1: Atrial Fibrillation Devices Market Drivers
  • Figure 2: Atrial Fibrillation Devices Market Restraints
  • Figure 3: Atrial Fibrillation Devices Market Opportunities
  • Figure 4: Impact Analysis: AI, Geopolitical, Trade, and Economic Developments
  • Figure 5: Regulatory Analysis of the Atrial Fibrillation Devices Market (the United States)
  • Figure 6: Regulatory Analysis of the Atrial Fibrillation Devices Market (Europe)
  • Figure 7: Regulatory Analysis of the Atrial Fibrillation Devices Market (Japan)
  • Figure 8: Regulatory Analysis of the Atrial Fibrillation Devices Market (China)
  • Figure 9: Porter's Five Forces Analysis of the Atrial Fibrillation Devices Market
  • Figure 10: Competitive Analysis of the Atrial Fibrillation Devices Market
  • Figure 11: Global Atrial Fibrillation Devices Market Size in USD million (2023-2034)
  • Figure 12: Global Atrial Fibrillation Devices Market Size by Product in USD million (2023-2034)
  • Figure 13: Global Atrial Fibrillation Devices Market Size by Ablation Technology in USD million (2023-2034)
  • Figure 14: Global Atrial Fibrillation Devices Market Size by Indication in USD million (2023-2034)
  • Figure 15: Global Atrial Fibrillation Devices Market Size by End-User in USD million (2023-2034)
  • Figure 16: Atrial Fibrillation Devices Market Size in North America in USD million (2023-2034)
  • Figure 17: Atrial Fibrillation Devices Market Size in the United States in USD million (2023-2034)
  • Figure 18: Atrial Fibrillation Devices Market Size in Canada in USD million (2023-2034)
  • Figure 19: Atrial Fibrillation Devices Market Size in Mexico in USD million (2023-2034)
  • Figure 20: Atrial Fibrillation Devices Market Size in Europe in USD million (2023-2034)
  • Figure 21: Atrial Fibrillation Devices Market Size in Germany in USD million (2023-2034)
  • Figure 22: Atrial Fibrillation Devices Market Size in the United Kingdom in USD million (2023-2034)
  • Figure 23: Atrial Fibrillation Devices Market Size in France in USD million (2023-2034)
  • Figure 24: Atrial Fibrillation Devices Market Size in Italy in USD million (2023-2034)
  • Figure 25: Atrial Fibrillation Devices Market Size in Spain in USD million (2023-2034)
  • Figure 26: Atrial Fibrillation Devices Market Size in the Rest of Europe in USD million (2023-2034)
  • Figure 27: Atrial Fibrillation Devices Market Size in Asia-Pacific in USD million (2023-2034)
  • Figure 28: Atrial Fibrillation Devices Market Size in China in USD million (2023-2034)
  • Figure 29: Atrial Fibrillation Devices Market Size in Japan in USD million (2023-2034)
  • Figure 30: Atrial Fibrillation Devices Market Size in India in USD million (2023-2034)
  • Figure 31: Atrial Fibrillation Devices Market Size in Australia in USD million (2023-2034)
  • Figure 32: Atrial Fibrillation Devices Market Size in South Korea in USD million (2023-2034)
  • Figure 33: Atrial Fibrillation Devices Market Size in the Rest of Asia-Pacific in USD million (2023-2034)
  • Figure 34: Atrial Fibrillation Devices Market Size in the Rest of the World in USD million (2023-2034)
  • Figure 35: Atrial Fibrillation Devices Market Size in the Middle East in USD million (2023-2034)
  • Figure 36: Atrial Fibrillation Devices Market Size in Africa in USD million (2023-2034)
  • Figure 37: Atrial Fibrillation Devices Market Size in South America in USD million (2023-2034)